Extended Half-Life Antibody

Advertisement

cGxPJobs Banner

Spyre Therapeutics Advances SPY003 in UC with Positive Phase 2 Data

WALTHAM, Mass. — September 8, 2026 Spyre Therapeutics announced positive 12-week induction results from Part A of the Phase...

By cGxPwire Editor
September 10, 2026

Read More

Advertisement

cGxPJobs

Directory